US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US5888767A
(en)
*
|
1996-11-27 |
1999-03-30 |
The Johns Hopkins University School Of Medicine |
Method of using a conditionally replicating viral vector to express a gene
|
EP1041152A1
(de)
|
1996-10-17 |
2000-10-04 |
Oxford Biomedica (UK) Limited |
Retrovirale Vektoren
|
US7198784B2
(en)
*
|
1996-10-17 |
2007-04-03 |
Oxford Biomedica (Uk) Limited |
Retroviral vectors
|
ES2245042T3
(es)
|
1997-09-24 |
2005-12-16 |
The Regents Of The University Of California |
Vectores de lentivirus de no primates y sistemas de empaquetamiento.
|
EP1025217B1
(de)
*
|
1997-10-24 |
2006-10-04 |
Invitrogen Corporation |
Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
|
US5994136A
(en)
*
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
DK1895010T3
(da)
*
|
1997-12-22 |
2011-11-21 |
Oxford Biomedica Ltd |
Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
|
US6387695B1
(en)
*
|
1997-12-23 |
2002-05-14 |
Merck & Co., Inc. |
DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
|
DE60042969D1
(de)
|
1999-03-02 |
2009-10-29 |
Life Technologies Corp |
Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
|
WO2000055378A1
(en)
*
|
1999-03-16 |
2000-09-21 |
Dana-Farber Cancer Institute, Inc. |
Lentiviral vector system for high quantity screening
|
US7262049B2
(en)
*
|
1999-03-16 |
2007-08-28 |
Dana-Farber Cancer Institute, Inc. |
Pseudotyped lentiviral vectors and uses thereof
|
IL146144A0
(en)
*
|
1999-04-29 |
2002-07-25 |
Cell Genesys Inc |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
KR20020028887A
(ko)
*
|
1999-06-22 |
2002-04-17 |
나카토미 히로타카 |
2개의 외래유전자를 발현시키기 위한 벡터
|
WO2001030847A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
KR100354562B1
(ko)
*
|
1999-12-06 |
2002-09-30 |
주식회사 제넥신 |
원숭이에서 SIVmac239의 감염에 대한 방어를유도하는 AIDS DNA 백신
|
AU785483B2
(en)
*
|
1999-12-10 |
2007-09-20 |
Invitrogen Corporation |
Use of multiple recombination sites with unique specificity in recombinational cloning
|
US6656706B2
(en)
*
|
1999-12-23 |
2003-12-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
|
ES2276788T3
(es)
|
2000-05-10 |
2007-07-01 |
Sanofi Pasteur Limited |
Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
|
JP2003534787A
(ja)
*
|
2000-05-26 |
2003-11-25 |
カイロン コーポレイション |
レンチウイルスベクターを使用する神経細胞の形質導入の方法
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US6852510B2
(en)
*
|
2000-07-03 |
2005-02-08 |
Gala Design Inc |
Host cells containing multiple integrating vectors
|
US20040235173A1
(en)
*
|
2000-07-03 |
2004-11-25 |
Gala Design, Inc. |
Production of host cells containing multiple integrating vectors by serial transduction
|
AU2001270252B2
(en)
*
|
2000-07-03 |
2007-02-08 |
Catalent Pharma Solutions, Llc |
Expression vectors
|
US20030224415A1
(en)
*
|
2001-06-29 |
2003-12-04 |
Gala Design, Inc. |
Selection free growth of host cells containing multiple integrating vectors
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6800281B2
(en)
*
|
2000-11-09 |
2004-10-05 |
Oxford Biomedica (Uk) Limited |
Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
|
US7575924B2
(en)
|
2000-11-13 |
2009-08-18 |
Research Development Foundation |
Methods and compositions relating to improved lentiviral vectors and their applications
|
US6712612B1
(en)
|
2000-12-12 |
2004-03-30 |
Genecure Llc |
Safe and stable retroviral helper cell line and related compositions and methods
|
US7122181B2
(en)
*
|
2000-12-19 |
2006-10-17 |
Research Development Foundation |
Lentiviral vector-mediated gene transfer and uses thereof
|
EP1343367A2
(de)
*
|
2000-12-20 |
2003-09-17 |
K.U. Leuven Research & Development |
Nicht-menschliches tierisches krankheitsmuster
|
DK2371854T3
(da)
|
2001-03-09 |
2014-08-11 |
Univ Texas |
Induktion af tumorimmunitet med varianter af folatbindende protein
|
EP1373536B9
(de)
*
|
2001-03-13 |
2009-09-02 |
Novartis AG |
Lentivirale verpackungskonstrukte
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
ATE541937T1
(de)
*
|
2001-04-06 |
2012-02-15 |
Univ Chicago |
Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie
|
US20040033604A1
(en)
*
|
2001-04-20 |
2004-02-19 |
Gary Kobinger |
Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains
|
AU2002307393A1
(en)
*
|
2001-04-20 |
2002-11-05 |
The Salk Institute For Biological Studies |
Inducible expression of transfected genes
|
WO2002092134A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
WO2002095002A2
(en)
|
2001-05-22 |
2002-11-28 |
University Of Chicago |
N4 virion single-stranded dna dependent rna polymerase
|
ITMI20011138A1
(it)
*
|
2001-05-29 |
2002-11-29 |
Uni Di Torino |
Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo
|
DE60228082D1
(de)
|
2001-05-31 |
2008-09-18 |
Novartis Ag |
Nten und neue liganden und pharmazeutische zusammensetzungen
|
CA2451173C
(en)
|
2001-06-29 |
2012-12-18 |
Sloan Kettering Institute For Cancer Research |
Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
|
IL160132A0
(en)
|
2001-08-02 |
2004-06-20 |
Inst Clayton De La Rech |
Methods and compositions relating to improved lentiviral vector production systems
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
AU2002327430A1
(en)
*
|
2001-08-08 |
2003-02-24 |
Genzyme Corporation |
Methods for treating diabetes and other blood sugar disorders
|
WO2003022040A2
(en)
*
|
2001-09-13 |
2003-03-20 |
California Institute Of Technology |
Method for producing transgenic animals
|
EP1438399A4
(de)
*
|
2001-09-28 |
2005-09-14 |
Univ North Carolina |
Paramyxoviren als vektoren für den gentransfer in lungenzellen
|
CA2915676C
(en)
|
2001-10-02 |
2017-06-06 |
Institut Clayton De La Recherche |
Restricted expression lentiviral vectors
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US20040038304A1
(en)
*
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
AU2004280608B2
(en)
*
|
2002-04-09 |
2012-04-05 |
Sanofi Pasteur, Inc. |
Modified CEA/B7 vector
|
ATE517122T1
(de)
|
2002-04-09 |
2011-08-15 |
Sanofi Pasteur Ltd |
Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
|
WO2003091442A1
(en)
|
2002-04-26 |
2003-11-06 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Improved chimeric glycoproteins and pseudotyped lentiviral vectors
|
WO2003093417A2
(en)
|
2002-05-01 |
2003-11-13 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
US20050214945A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Eastern Virginia Medical School |
Htlv-I tax induced killing of p53 null cancer cells
|
US20040009158A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Washington University |
Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
|
AU2003302724A1
(en)
*
|
2002-08-13 |
2004-07-09 |
Mcivor, Scott, R. |
Methods of using vectors to treat metabolic disorders
|
WO2004024683A2
(en)
*
|
2002-09-13 |
2004-03-25 |
University Of Maryland Biotechnology |
COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR
|
CA2506798C
(en)
*
|
2002-11-22 |
2013-01-22 |
Institut Clayton De La Recherche |
Compositions and systems for the regulation of genes
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
RU2353357C2
(ru)
|
2003-05-16 |
2009-04-27 |
Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют |
Композиции для супрессии экспрессии ccr5 и способы их применения
|
US20050036988A1
(en)
*
|
2003-05-28 |
2005-02-17 |
Ruian Xu |
Compositions and methods for preventing and treating liver cirrhosis
|
US7696322B2
(en)
*
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
US20050196381A1
(en)
*
|
2003-09-09 |
2005-09-08 |
Xiaobin Lu |
Lentivirus vector-based approaches for generating an immune response to HIV in humans
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
JP2007512838A
(ja)
|
2003-12-01 |
2007-05-24 |
インヴィトロジェン コーポレーション |
組換え部位を含む核酸分子およびその使用方法
|
US20050221429A1
(en)
*
|
2004-01-16 |
2005-10-06 |
Cardinal Health Pts, Llc |
Host cells containing multiple integrating vectors comprising an amplifiable marker
|
WO2005100393A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating cardiac contractility
|
CA2561714A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
WO2006017279A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
DE602005021811D1
(de)
|
2004-09-13 |
2010-07-22 |
Genzyme Corp |
Multimere konstrukte
|
AU2006214278C1
(en)
|
2005-02-16 |
2012-07-19 |
Miltenyi Biotec Technology, Inc. |
Lentiviral vectors and their use
|
EP3312196B1
(de)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antikörper gegen cd38 zur behandlung von multiplem myelom
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
LT1988823T
(lt)
|
2006-02-09 |
2018-12-10 |
Genzyme Corporation |
Lėtas intraventrikuliarinis pateikimas
|
EP1835032A1
(de)
|
2006-03-14 |
2007-09-19 |
Université de Liège |
Selbst-inaktivierender rekombinanter lentiviraler Vektor zur Inhibierung von HIV
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
JP5623740B2
(ja)
|
2006-07-25 |
2014-11-12 |
セラドン・コーポレーション |
遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
|
WO2008014484A1
(en)
|
2006-07-27 |
2008-01-31 |
University Of Maryland, Baltimore |
Cellular receptor for antiproliferative factor
|
WO2008066658A2
(en)
|
2006-11-03 |
2008-06-05 |
The Trustees Of Princeton University |
Engineered cellular pathways for programmed autoregulation of differentiation
|
WO2008069663A1
(en)
|
2006-12-07 |
2008-06-12 |
Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum |
Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
|
EP2155860B1
(de)
|
2007-05-03 |
2014-08-27 |
The Brigham and Women's Hospital, Inc. |
Multipotente stammzellen und ihre verwendung
|
ATE553771T1
(de)
*
|
2007-06-06 |
2012-05-15 |
Res Dev Foundation |
Rtef-1-varianten und deren verwendung zur inhibierung von angiogenese
|
WO2009014708A2
(en)
*
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
US8425897B2
(en)
*
|
2007-08-30 |
2013-04-23 |
Immutep S.A. |
Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
|
JP2011500036A
(ja)
|
2007-10-15 |
2011-01-06 |
ザ ユニバーシティー オブ クイーンズランド |
構築物系およびその使用
|
WO2009054985A1
(en)
|
2007-10-25 |
2009-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
PL2222697T3
(pl)
|
2007-11-01 |
2013-05-31 |
Astellas Pharma Inc |
Immunosupresyjne polipeptydy i kwasy nukleinowe
|
MX2010007530A
(es)
|
2008-01-10 |
2010-11-10 |
Res Dev Foundation |
Vacunas y diagnosticos para ehrlichiosis.
|
PL2245464T3
(pl)
|
2008-01-25 |
2017-08-31 |
Multivir Inc. |
Biomarkery p53
|
KR100981092B1
(ko)
|
2008-02-29 |
2010-09-08 |
고려대학교 산학협력단 |
제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
|
EP3409762A1
(de)
|
2008-03-17 |
2018-12-05 |
The Scripps Research Institute |
Kombinierte chemische und genetische ansätze zur erzeugung von induzierten pluripotenten stammzellen
|
US20110142880A1
(en)
*
|
2008-03-28 |
2011-06-16 |
Franck Yann Lemiale |
Lentivirus-based immunogenic vectors
|
CA2721870C
(en)
|
2008-04-21 |
2020-12-22 |
Tissue Regeneration Therapeutics, Inc. |
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
|
EP3330371A1
(de)
|
2008-08-12 |
2018-06-06 |
Cellular Dynamics International, Inc. |
Verfahren zur herstellung von ips-zellen
|
AU2009282625A1
(en)
|
2008-08-18 |
2010-02-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Derivatives of APF and methods of use
|
US8840881B2
(en)
|
2008-08-28 |
2014-09-23 |
Aduro Gvax Inc. |
Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
|
CN102317442B
(zh)
|
2008-12-17 |
2014-08-13 |
斯克里普斯研究所 |
干细胞的产生和保持
|
WO2010087702A1
(en)
|
2009-01-30 |
2010-08-05 |
Stichting Katholieke Universiteit |
TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
|
EP3441458B9
(de)
|
2009-02-03 |
2023-08-23 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Nährmedium für epithelstammzellen und organelle mit den besagten stammzellen
|
US9752124B2
(en)
|
2009-02-03 |
2017-09-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising the stem cells
|
EP2412800A1
(de)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Leberorganoid, Verwendungen davon und Kultivierungsverfahren zum Erhalten davon
|
RU2012140691A
(ru)
*
|
2009-03-13 |
2014-03-27 |
Лентиген Корпорейшен |
Вакцины на основе неинтегрирующегося ретровирусного вектора
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
ES2568938T3
(es)
|
2009-04-28 |
2016-05-05 |
Vanderbilt University |
Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
|
SG178194A1
(en)
|
2009-07-31 |
2012-03-29 |
Baxter Int |
Cell culture medium for adamts protein expression
|
WO2011034421A1
(en)
|
2009-09-16 |
2011-03-24 |
Stichting Het Nederlands Kanker Instituut |
Fra-1 target genes as drug targets for treating cancer
|
EP2305717A1
(de)
|
2009-09-21 |
2011-04-06 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Hemmung von TNIK zur Behandlung von Darmkrebs
|
DK3167897T3
(da)
|
2009-09-21 |
2021-04-19 |
Baxalta GmbH |
Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
|
CN102741394B
(zh)
|
2009-10-16 |
2016-05-04 |
斯克里普斯研究所 |
多能细胞的诱导
|
EP2534163B1
(de)
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Gezielte genommodifikation mit partiell einsträngigen donatormolekülen
|
US10787701B2
(en)
|
2010-04-05 |
2020-09-29 |
Prognosys Biosciences, Inc. |
Spatially encoded biological assays
|
CA2796601C
(en)
|
2010-04-19 |
2019-03-26 |
Research Development Foundation |
Rtef-1 variants and uses thereof
|
US9795658B2
(en)
|
2010-04-20 |
2017-10-24 |
Admedus Vaccines Pty Ltd |
Expression system for modulating an immune response
|
BR112012030522A2
(pt)
*
|
2010-05-27 |
2020-10-13 |
Heinrich-Pette-Institut Leibniz-Institut Fur Experimentelle Virologie - Stiftung Burgerlichen Rechts |
Método para preparo de um vetor de expressão que codifica uma recombinase configurada, método para preparo de uma célula transformada, ácido nucleico, recombinase configurada codificada pelo ácido nucleico, célula transformada ecomposição farmacêutica"
|
CA2802087A1
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
A compendium of ready-built stem cell models for interrogation of biological response
|
EP2591093B1
(de)
|
2010-07-07 |
2018-11-28 |
FUJIFILM Cellular Dynamics, Inc. |
Endothelzellenproduktion durch programmierung
|
ES2761692T5
(es)
|
2010-07-08 |
2023-07-05 |
Takeda Pharmaceuticals Co |
Método de producción de vWF recombinante de alto peso molecular en cultivo celular
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
US20120083035A1
(en)
*
|
2010-09-30 |
2012-04-05 |
Dharmacon, Inc. |
Modified Cell Lines for Increasing Lentiviral Titers
|
WO2012047093A1
(en)
|
2010-10-05 |
2012-04-12 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Treatment of the sjögren's syndrome
|
EP2465928A1
(de)
|
2010-12-16 |
2012-06-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Behandlung von Th17-vermittelten Krankheiten
|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
BRPI1105317A2
(pt)
|
2011-01-24 |
2013-04-30 |
Fundacco Hemoct De Ribeirco Preto |
produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
|
CA2826386C
(en)
|
2011-02-08 |
2020-04-28 |
Cellular Dynamics International, Inc. |
Hematopoietic precursor cell production by programming
|
WO2012119095A1
(en)
|
2011-03-02 |
2012-09-07 |
Board Of Regents, The University Of Texas System |
Fus1/tusc2 therapies
|
EP2710130B1
(de)
|
2011-05-19 |
2022-06-29 |
Fundación Pública Andaluza Progreso Y Salud |
Effizient induzierbare lentivirale tet-on-vektor system mit zwei-promotoren
|
ES2710452T3
(es)
|
2011-06-10 |
2019-04-25 |
Bluebird Bio Inc |
Vectores de terapia génica para la adrenoleucodistrofia y la adrenomieloneuropatía
|
CA2841165A1
(en)
|
2011-07-11 |
2013-01-17 |
Cellular Dynamics International, Inc. |
Methods for cell reprogramming and genome engineering
|
WO2013026015A1
(en)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Muc1 ligand traps for use in treating cancers
|
AU2011377617B2
(en)
|
2011-09-23 |
2018-03-08 |
Bluebird Bio, Inc. |
Improved gene therapy methods
|
IN2014CN02518A
(de)
|
2011-09-30 |
2015-07-31 |
Bluebird Bio Inc |
|
CN110777124A
(zh)
|
2011-10-27 |
2020-02-11 |
威尔斯达眼科制剂公司 |
编码视杆细胞来源的视锥细胞活力因子的载体
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
WO2013181326A1
(en)
|
2012-05-30 |
2013-12-05 |
Cornell University |
Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
|
WO2014003553A1
(en)
|
2012-06-27 |
2014-01-03 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
RS54944B1
(sr)
|
2012-07-12 |
2016-11-30 |
Proqr Therapeutics Ii Bv |
Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
|
PL2880167T3
(pl)
|
2012-07-31 |
2018-12-31 |
The Board Of Regents Of The University Of Texas System |
Sposoby i kompozycje do indukcji tworzenia trzustkowych komórek beta in vivo
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
EP2895611A4
(de)
*
|
2012-09-14 |
2016-04-27 |
Univ California |
Lentivirale vektoren zur stammzellengentherapie von sichelzellanämie
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
NZ750426A
(en)
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
HRP20231183T1
(hr)
|
2013-02-15 |
2024-01-05 |
Bioverativ Therapeutics Inc. |
Optimizirani gen faktora viii
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
WO2014132137A2
(en)
|
2013-03-01 |
2014-09-04 |
Université De Genève |
Transgenic cell selection
|
AU2014225708B2
(en)
|
2013-03-05 |
2018-10-18 |
Baylor College Of Medicine |
Heparanase expression in human T lymphocytes
|
CA2904230A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
AU2014225365B2
(en)
|
2013-03-07 |
2019-09-12 |
Baylor College Of Medicine |
Targeting CD138 in cancer
|
EP2964764A1
(de)
|
2013-03-09 |
2016-01-13 |
Baylor College Of Medicine |
Auf gefässe abzielende t-zelltherapie
|
AU2013202965B2
(en)
|
2013-03-15 |
2016-07-21 |
Takeda Pharmaceutical Company Limited |
Improved method for producing factor h from a plasma precipitation fraction
|
PT2970920T
(pt)
|
2013-03-15 |
2018-07-30 |
Childrens Hospital Philadelphia |
Processo de fabrico escalável para produzir vetores lentivirais recombinantes em sistema de cultura de células de suspensão livres de soro
|
WO2014152177A1
(en)
|
2013-03-15 |
2014-09-25 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
EP2970892A1
(de)
|
2013-03-15 |
2016-01-20 |
The Jackson Laboratory |
Isolierung nichtembryonischer stammzellen und verwendungen davon
|
EP3789487A1
(de)
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Wirksame erzeugung von tumorgerichteten, aus pluripotenten stammzellen gewonnenen t-zellen
|
DK3013983T3
(da)
|
2013-06-25 |
2023-03-06 |
Prognosys Biosciences Inc |
Spatialt kodede biologiske assays ved brug af en mikrofluidisk anordning
|
JP2016531147A
(ja)
|
2013-09-09 |
2016-10-06 |
フィジーン、エルエルシーFigene, Llc |
コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
|
EP3065711A4
(de)
|
2013-11-05 |
2017-06-21 |
Takara Bio USA, Inc. |
Trockene transfektionszusammensetzungen und verfahren zur herstellung und verwendung davon
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
CA2929555A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US20160376375A1
(en)
|
2013-11-27 |
2016-12-29 |
Baylor College Of Medicine |
CSGP4 - Specific Chimeric Antigen Receptor for Cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
CN106132992B
(zh)
|
2014-01-29 |
2020-08-07 |
达娜-法勃肿瘤研究所公司 |
针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
|
CA2940765A1
(en)
|
2014-02-25 |
2015-09-03 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
PT3114214T
(pt)
|
2014-03-04 |
2024-01-03 |
Fate Therapeutics Inc |
Métodos de reprogramação melhorados e plataformas de cultura celular
|
US10000741B2
(en)
|
2014-03-17 |
2018-06-19 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
BR112016024481A2
(pt)
|
2014-04-25 |
2017-10-10 |
Bluebird Bio Inc |
receptores quiméricos de antígenos com promotor mnd
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
EP2957634A1
(de)
|
2014-06-20 |
2015-12-23 |
Consejo Superior De Investigaciones Científicas |
Verbindungen zur Prävention und/oder Behandlung von fibrotischen Erkrankungen
|
EP3160478A4
(de)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-ix-gen
|
JP6754761B2
(ja)
|
2014-07-11 |
2020-09-16 |
セルジーン コーポレイション |
Tリンパ球へのベクター導入効率の改善方法
|
SG10201900455YA
(en)
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
EP2977463A1
(de)
|
2014-07-25 |
2016-01-27 |
Centro de Investigación Biomédica en Red (CIBER) |
Verfahren und Wirkstoffe im Zusammenhang mit Lungenerkrankungen
|
JP2017522895A
(ja)
|
2014-07-31 |
2017-08-17 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ |
哺乳類rpe65の高イソメロヒドロラーゼ活性突然変異体
|
CN106795497A
(zh)
|
2014-08-12 |
2017-05-31 |
人类起源公司 |
被工程化以归巢至淋巴结b细胞区、皮肤或胃肠道的car‑t淋巴细胞
|
WO2016025510A1
(en)
|
2014-08-12 |
2016-02-18 |
Rappolee Daniel A |
Systems and methods to detect stem cell stress and uses thereof
|
EP3186284B1
(de)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
|
WO2016030501A1
(en)
|
2014-08-28 |
2016-03-03 |
Centre National De La Recherche Scientifique - Cnrs - |
Synthetic alu-retrotransposon vectors for gene therapy
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
PT3194602T
(pt)
|
2014-09-18 |
2020-03-03 |
British Columbia Cancer Agency Branch |
Compostos e métodos para aumentar a transferência de genes virais para células hematopoiéticas humanas
|
ES2844700T3
(es)
|
2014-09-26 |
2021-07-22 |
Baylor College Medicine |
Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
|
BR112017012502B1
(pt)
|
2014-12-12 |
2020-09-15 |
Bluebird Bio, Inc. |
Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
|
CN108064252A
(zh)
|
2014-12-19 |
2018-05-22 |
达纳-法伯癌症研究所公司 |
嵌合抗原受体及其使用方法
|
EP3757211A1
(de)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
EP3233901A1
(de)
|
2014-12-19 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Carboanhydrase-ix-spezifische chimäre antigenrezeptoren und verfahren zur verwendung davon
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3978614A3
(de)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
|
GB201500374D0
(en)
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
JP6871866B2
(ja)
|
2015-02-03 |
2021-05-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗rho gtpaseコンホーメーションシングルドメイン抗体及びその使用
|
WO2016134293A1
(en)
|
2015-02-20 |
2016-08-25 |
Baylor College Of Medicine |
p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
|
EP3265178A4
(de)
|
2015-03-02 |
2018-09-05 |
Adverum Biotechnologies, Inc. |
Zusammensetzungen und verfahren zur intravitrealen abgabe von polynukleotiden an retinakonen
|
US20180271891A1
(en)
|
2015-03-11 |
2018-09-27 |
The Broad Institute Inc. |
Selective treatment of prmt5 dependent cancer
|
EP3286225B1
(de)
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Chimärer cd5-antigenrezeptor für adoptive t-zelltherapie
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
WO2016185026A1
(en)
|
2015-05-20 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
WO2017004579A1
(en)
|
2015-07-01 |
2017-01-05 |
O'connor Colleen M |
Artificial antigen presenting cells for adoptive cell therapy against cancer
|
JP2018529759A
(ja)
|
2015-08-14 |
2018-10-11 |
ザ ユニバーシティー オブ シドニー |
治療用コネキシン45阻害剤
|
JP6980659B2
(ja)
|
2015-08-31 |
2021-12-15 |
ヘリックスミス カンパニー, リミテッド |
抗シアリルtnキメラ抗原受容体
|
WO2017055248A1
(en)
|
2015-09-28 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of heart failure
|
JP7263005B2
(ja)
|
2015-10-16 |
2023-04-24 |
フェイト セラピューティクス,インコーポレイテッド |
基底状態の多能性の誘導及び維持に関するプラットフォーム
|
JP6976939B2
(ja)
|
2015-10-20 |
2021-12-08 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
遺伝的プログラミングによる多系統造血前駆細胞の作製
|
MA45426A
(fr)
|
2015-10-22 |
2019-05-01 |
Juno Therapeutics Gmbh |
Procédés, kits, agents et appareils de transduction
|
CN115105500A
(zh)
|
2015-10-23 |
2022-09-27 |
杰克逊实验室 |
烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼
|
KR20180083868A
(ko)
|
2015-10-30 |
2018-07-23 |
알레타 바이오쎄라퓨틱스, 인크. |
종양 형질도입용 조성물 및 방법
|
MA43135A
(fr)
|
2015-10-30 |
2018-09-05 |
Aleta Biotherapeutics Inc |
Compositions et méthodes pour le du traitement du cancer
|
ES2892972T3
(es)
|
2015-11-02 |
2022-02-07 |
Univ Texas |
Métodos de activación de CD40 y bloqueo de punto de control inmunitario
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
EA038288B1
(ru)
|
2015-11-13 |
2021-08-05 |
Такеда Фармасьютикал Компани Лимитед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
|
AU2016354550B2
(en)
|
2015-11-13 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
CN108601951B
(zh)
|
2015-12-09 |
2022-11-22 |
金港医疗(澳大利亚)私人有限公司 |
用于治疗的免疫调节组合物
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
SI3411478T1
(sl)
|
2016-02-01 |
2022-10-28 |
Bioverativ Therapeutics Inc. |
Optimirani geni dejavnika VIII
|
US11326183B2
(en)
|
2016-02-12 |
2022-05-10 |
Bluebird Bio, Inc. |
VCN enhancer compositions and methods of using the same
|
KR20180110112A
(ko)
|
2016-02-12 |
2018-10-08 |
블루버드 바이오, 인코포레이티드. |
Vcn 인핸서 조성물 및 이의 사용 방법
|
WO2017143076A1
(en)
|
2016-02-16 |
2017-08-24 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
US11225520B2
(en)
|
2016-02-16 |
2022-01-18 |
Dana-Farber Cancer Institute, Inc. |
Immunotherapy compositions and methods
|
US10435682B2
(en)
|
2016-02-19 |
2019-10-08 |
University Of South Florida |
Arginine deiminase gene therapy for disordered proteins
|
EP3436049B1
(de)
|
2016-03-31 |
2022-01-12 |
Baylor Research Institute |
Angiopoietin-ähnliches protein 8 (angptl8)
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CA3020993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
US20190125826A1
(en)
|
2016-04-22 |
2019-05-02 |
Inserm (Institut National De La Santé Et De La Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
CA3026180A1
(en)
|
2016-06-10 |
2017-12-14 |
Gadeta B.V. |
Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
|
CA3029582A1
(en)
|
2016-07-01 |
2018-01-04 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
WO2018023094A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
EP3491134B1
(de)
|
2016-08-01 |
2023-10-11 |
University of Pittsburgh - of The Commonwealth System of Higher Education |
Menschliche induzierte pluripotente stammzellen zur hocheffizienten genmanipulation
|
EP3500696A4
(de)
|
2016-08-16 |
2020-04-08 |
Bluebird Bio, Inc. |
Il-10-rezeptor-alpha-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
|
US20190262398A1
(en)
|
2016-08-23 |
2019-08-29 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
EP3504223A4
(de)
|
2016-08-26 |
2020-03-25 |
Baylor College of Medicine |
Konstitutiv aktive cytokin-rezeptoren für die zelltherapie
|
CA3035455A1
(en)
|
2016-09-08 |
2018-03-15 |
Bluebird Bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
DK3757120T3
(da)
|
2016-10-04 |
2022-07-25 |
Prec Biosciences Inc |
Co-stimulerende domæner til anvendelse i genetisk modificerede celler
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
AU2017340644B2
(en)
|
2016-10-05 |
2024-05-09 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for directed differentiation of pluripotent stem cells to HLA homozygous immune cells
|
CN110072593A
(zh)
|
2016-10-05 |
2019-07-30 |
法国国家健康和医学研究院 |
适用于肾癌治疗的方法和药物组合物
|
CN116672456A
(zh)
|
2016-10-12 |
2023-09-01 |
得克萨斯州大学系统董事会 |
用于tusc2免疫治疗的方法和组合物
|
MX2019004259A
(es)
|
2016-10-12 |
2019-09-27 |
Bioverativ Usa Inc |
Anticuerpos anti-c1s y metodos de uso de los mismos.
|
WO2018069422A1
(en)
|
2016-10-12 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease
|
US11530395B2
(en)
|
2016-10-17 |
2022-12-20 |
2Seventy Bio, Inc. |
TGFBetaR2 endonuclease variants, compositions, and methods of use
|
EP3528851B1
(de)
|
2016-10-20 |
2022-04-27 |
Celgene Corporation |
Cereblon-basierte heterodimerisierbare chimäre antigenrezeptoren
|
WO2018083538A1
(en)
|
2016-11-07 |
2018-05-11 |
Neuracle Scienc3 Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
MX2019005724A
(es)
|
2016-11-17 |
2019-07-08 |
Bluebird Bio Inc |
Conversor de se?ales de tgfbeta.
|
WO2018091621A1
(en)
|
2016-11-17 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
WO2018106724A1
(en)
|
2016-12-05 |
2018-06-14 |
The Regents Of The University Of California |
Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
|
US20190350978A1
(en)
|
2016-12-05 |
2019-11-21 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
CA3046961A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018130518A1
(en)
|
2017-01-10 |
2018-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inducing senescence in cancer cells
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
EP3574104A1
(de)
|
2017-01-30 |
2019-12-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Rekombinante virusvektoren zur behandlung der glykogenspeicherkrankheit
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
US11530388B2
(en)
|
2017-02-14 |
2022-12-20 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Methods of engineering human induced pluripotent stem cells to produce liver tissue
|
EP3583203B1
(de)
|
2017-02-15 |
2023-11-01 |
2seventy bio, Inc. |
Spenderreparaturtemplates für multiplex-genomeditierung
|
EP3600447A4
(de)
|
2017-03-20 |
2020-12-30 |
Baylor College of Medicine |
Transgene c-mpl für ligandenabhängige co-stimulation und cytokinsignale für tcr-manipulierte zellen
|
AU2018246143A1
(en)
|
2017-03-28 |
2019-10-31 |
The Trustees Of The University Of Pennsylvania |
Methods to protect transplanted tissue from rejection
|
EP3388520A1
(de)
|
2017-04-11 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur reduzierung der expression von nkcc1 in einer darauf angewiesenen person
|
US20200123501A1
(en)
|
2017-04-18 |
2020-04-23 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
AU2018261637A1
(en)
|
2017-05-03 |
2019-12-12 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells.
|
CA3062698A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
KR102551733B1
(ko)
|
2017-05-22 |
2023-07-06 |
다케다 야쿠힌 고교 가부시키가이샤 |
B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
|
EP3630160A1
(de)
|
2017-05-24 |
2020-04-08 |
Universitat Autònoma De Barcelona |
Konstrukt zur viralen expression mit einer codierungssequenz des fibroblasten-wachstumsfaktors 21 (fgf21)
|
MA48797A
(fr)
|
2017-05-25 |
2020-04-08 |
Bluebird Bio Inc |
Variants de l'endonucléase cblb , compositions et procédés d'utilisation
|
KR20230142819A
(ko)
|
2017-06-27 |
2023-10-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
WO2019003159A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
|
EP3645044A4
(de)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
Verwendung von anti-familie mit sequenzähnlichkeit 19, element-a5-antikörpern zur behandlung von glaukom
|
KR102574549B1
(ko)
|
2017-06-27 |
2023-09-07 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
US11053484B2
(en)
|
2017-06-30 |
2021-07-06 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
MX2020000900A
(es)
|
2017-07-29 |
2021-01-08 |
Juno Therapeutics Inc |
Reactivos para expandir celulas que expresan receptores recombinantes.
|
WO2019027299A2
(ko)
*
|
2017-08-04 |
2019-02-07 |
주식회사 에스엘바이젠 |
간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
|
US11851678B2
(en)
|
2017-08-09 |
2023-12-26 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
WO2019057742A1
(en)
|
2017-09-20 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA
|
EP3692368A1
(de)
|
2017-09-25 |
2020-08-12 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verwendung von vnn1 als biomarker und therapeutisches target bei sarkomen
|
US20200239544A1
(en)
|
2017-10-03 |
2020-07-30 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
US11779654B2
(en)
|
2017-10-04 |
2023-10-10 |
2Seventy Bio, Inc. |
PCSK9 endonuclease variants, compositions, and methods of use
|
US11192944B2
(en)
|
2017-10-11 |
2021-12-07 |
Bioverativ Usa Inc. |
Methods of inducing complement activity
|
MX2020004240A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Proceso para generar composiciones terapeuticas de celulas modificadas.
|
EP3704229B1
(de)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung einer t-zell-zusammensetzung
|
JP2021502094A
(ja)
|
2017-11-10 |
2021-01-28 |
ジュノー セラピューティクス インコーポレイテッド |
閉鎖系極低温容器
|
EP3720480A2
(de)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Phänotypische marker für zelltherapie und verwandte verfahren
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
CA3086765A1
(en)
|
2017-12-28 |
2019-07-04 |
Tract Pharmaceuticals, Inc. |
Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
JP2021511802A
(ja)
|
2018-01-31 |
2021-05-13 |
ジュノー セラピューティクス インコーポレイテッド |
複製可能ウイルスの存在または非存在を評価するための方法および試薬
|
SG11202007114VA
(en)
|
2018-02-01 |
2020-08-28 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
CN112105731A
(zh)
|
2018-03-30 |
2020-12-18 |
日内瓦大学 |
微小rna表达构建体及其用途
|
CN112262214A
(zh)
|
2018-04-12 |
2021-01-22 |
优莫佳生物制药股份有限公司 |
病毒载体及包装细胞系
|
WO2019207513A1
(en)
|
2018-04-24 |
2019-10-31 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
CA3099497A1
(en)
|
2018-05-15 |
2019-11-21 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
DK3806903T3
(da)
|
2018-06-14 |
2024-04-15 |
2Seventy Bio Inc |
Cd79a kimæriske antigenreceptorer
|
WO2019238934A1
(en)
|
2018-06-15 |
2019-12-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the apolipoprotein m for the treatment and diagnosis of insulin resistance
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
EP3820509A1
(de)
|
2018-07-09 |
2021-05-19 |
Flagship Pioneering Innovations V, Inc. |
Fusosomzusammensetzungen und verwendungen davon
|
CN112689516A
(zh)
|
2018-07-11 |
2021-04-20 |
细胞基因公司 |
抗bcma嵌合抗原受体的用途
|
MX2021000582A
(es)
|
2018-07-16 |
2021-04-12 |
Baxalta Inc |
Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
WO2020049169A1
(en)
|
2018-09-06 |
2020-03-12 |
Centre Léon-Bérard |
Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
|
US20220031807A1
(en)
|
2018-09-27 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition reducing skin inflammation
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3873943A2
(de)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Verfahren zur behandlung mittels chimärer antigen-rezeptoren spezifisch für b-zellen-reifungsantigen
|
CA3120282A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
SG11202105079QA
(en)
|
2018-11-14 |
2021-06-29 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions for cns delivery
|
CA3119341A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
EP3884058A1
(de)
|
2018-11-21 |
2021-09-29 |
Umoja Biopharma, Inc. |
Multicistronischer vektor zum oberflächen-engineering von lentiviralen teilchen
|
US20210386870A1
(en)
|
2018-11-26 |
2021-12-16 |
Universitat Autònoma De Barcelona |
Fibroblast growth factor 21 (FGF21) gene therapy
|
EP3887518A2
(de)
|
2018-11-28 |
2021-10-06 |
Board of Regents, The University of Texas System |
Multiplexe genomeditierung von immunzellen zur erhöhung der funktionalität und resistenz gegenüber einer suppressiven umgebung
|
KR20210096648A
(ko)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
EP3886894B1
(de)
|
2018-11-30 |
2024-03-13 |
Juno Therapeutics, Inc. |
Verfahren zur dosierung und behandlung von b-zell-malignomen in der adoptiven zelltherapie
|
JP2022514465A
(ja)
|
2018-12-06 |
2022-02-14 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子を発現するレンチウイルスベクターの使用
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
US20220056092A1
(en)
|
2018-12-11 |
2022-02-24 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
BR112021012278A2
(pt)
|
2018-12-21 |
2021-12-14 |
Biontech Us Inc |
Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
|
TW202039546A
(zh)
|
2019-01-16 |
2020-11-01 |
美商巴克斯歐塔公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
US11596671B2
(en)
|
2019-02-01 |
2023-03-07 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
|
MX2021010840A
(es)
|
2019-03-08 |
2022-01-19 |
Obsidian Therapeutics Inc |
Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
|
SG11202109225WA
(en)
|
2019-03-08 |
2021-09-29 |
Obsidian Therapeutics Inc |
Cd40l compositions and methods for tunable regulation
|
CN113661180A
(zh)
|
2019-03-27 |
2021-11-16 |
宾夕法尼亚大学董事会 |
Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
US20220226501A1
(en)
|
2019-05-31 |
2022-07-21 |
Universitat Autònoma De Barcelona |
Insulin gene therapy
|
MX2021015125A
(es)
|
2019-06-07 |
2022-04-06 |
Juno Therapeutics Inc |
Cultivo automatizado de celulas t.
|
KR20220044266A
(ko)
|
2019-06-12 |
2022-04-07 |
옵시디안 테라퓨틱스, 인크. |
조정 가능한 조절을 위한 ca2 조성물 및 방법
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
US20220267398A1
(en)
|
2019-06-12 |
2022-08-25 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
EP3756680A1
(de)
|
2019-06-26 |
2020-12-30 |
Universitat de Lleida |
Zwischenfilament-abgeleitete peptide und deren verwendungen
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
CN114600172A
(zh)
|
2019-08-30 |
2022-06-07 |
朱诺治疗学股份有限公司 |
用于将细胞分类的机器学习方法
|
AU2020341454A1
(en)
|
2019-09-03 |
2022-03-10 |
Sana Biotechnology, Inc. |
CD24-associated particles and related methods and uses thereof
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
US20220332780A1
(en)
|
2019-09-10 |
2022-10-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
CA3155930A1
(en)
|
2019-09-27 |
2021-04-01 |
Starkage Therapeutics |
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
JP2022551483A
(ja)
|
2019-10-08 |
2022-12-09 |
トラスティーズ オブ ボストン カレッジ |
複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
|
WO2021076788A2
(en)
|
2019-10-16 |
2021-04-22 |
Umoja Biopharma, Inc. |
Retroviral vector for univeral receptor therapy
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
KR20220131892A
(ko)
|
2019-11-05 |
2022-09-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료용 t 세포 조성물의 속성 결정 방법
|
CA3160178A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
AU2020395318A1
(en)
|
2019-12-06 |
2022-06-09 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
|
JP2023506171A
(ja)
|
2019-12-12 |
2023-02-15 |
武田薬品工業株式会社 |
発現が上昇した組換えfviiiバリアントをコードするウイルスベクターを使用する、血友病aの遺伝子療法
|
US20230056856A1
(en)
|
2020-01-08 |
2023-02-23 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
JP2023512456A
(ja)
|
2020-01-13 |
2023-03-27 |
ネオイミューンテック, インコーポレイテッド |
Il-7タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
|
EP4093752A2
(de)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimäre polypeptide
|
WO2021151001A1
(en)
|
2020-01-22 |
2021-07-29 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
CN115315269A
(zh)
|
2020-01-24 |
2022-11-08 |
朱诺治疗学股份有限公司 |
在过继细胞疗法中给药和治疗滤泡性淋巴瘤和边缘区淋巴瘤的方法
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
WO2021154839A1
(en)
|
2020-01-30 |
2021-08-05 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
EP4100043A1
(de)
|
2020-02-04 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Tafa4 -polypeptid oder polynukleotid zum behandeln einer entzündungserkrankung
|
US20230210952A1
(en)
|
2020-02-05 |
2023-07-06 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
WO2021174004A1
(en)
|
2020-02-28 |
2021-09-02 |
Millennium Pharmaceuticals, Inc. |
Method for producing natural killer cells from pluripotent stem cells
|
AU2021230476A1
(en)
|
2020-03-02 |
2022-10-20 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed microRNAs
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
CN115768899A
(zh)
|
2020-03-09 |
2023-03-07 |
詹森生物科技公司 |
用于定量重组载体核酸整合的组合物和方法
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
JP2023517222A
(ja)
|
2020-03-11 |
2023-04-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
操作されたウイルス粒子を使用した遺伝子送達のための方法および組成物
|
BR112022018615A2
(pt)
|
2020-03-19 |
2022-12-20 |
Trizell Ltd |
Sistema de armazenamento de vírus sensível à temperatura
|
US20210322471A1
(en)
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
US20210324332A1
(en)
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
CN116096866A
(zh)
|
2020-03-31 |
2023-05-09 |
萨那生物科技公司 |
靶向脂质颗粒及其组合物和用途
|
WO2021198781A2
(en)
|
2020-04-02 |
2021-10-07 |
Takeda Pharmaceutical Company Limited |
Adamts13 variant, compositions, and uses thereof
|
BR112022020333A2
(pt)
|
2020-04-10 |
2022-11-22 |
Juno Therapeutics Inc |
Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
|
WO2021207636A2
(en)
|
2020-04-10 |
2021-10-14 |
Sola Biosciences Llc |
Compositions and methods for the treatment of protein aggregation disorders
|
EP4143327A1
(de)
|
2020-04-27 |
2023-03-08 |
Juno Therapeutics, Inc. |
Stabilisierung der grösse und aktivität eines polyethylenimin-desoxyribonukleinsäurekomplexes
|
EP4143215A2
(de)
|
2020-04-28 |
2023-03-08 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von tdp-43-proteinopathien
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
IL298532A
(en)
|
2020-05-26 |
2023-01-01 |
Univ Barcelona Autonoma |
Gene therapy for diseases related to the central nervous system using fibroblast growth factor 21 (fgf21)
|
US20230242643A1
(en)
|
2020-05-27 |
2023-08-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
AU2021280343A1
(en)
|
2020-05-29 |
2022-12-08 |
FUJIFILM Cellular Dynamics, Inc. |
Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
|
MX2022015002A
(es)
|
2020-05-29 |
2023-03-03 |
Fujifilm Cellular Dynamics Inc |
Bicapa del epitelio pigmentario de la retina y fotorreceptores y uso de los mismos.
|
WO2021248038A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
TW202208619A
(zh)
|
2020-06-24 |
2022-03-01 |
美商百歐維拉提夫治療公司 |
用於純化病毒載體之方法
|
CN115884986A
(zh)
|
2020-06-29 |
2023-03-31 |
Inserm(法国国家健康医学研究院) |
抗蛋白s单域抗体和包含其的多肽
|
JP2023540429A
(ja)
|
2020-07-10 |
2023-09-25 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
てんかんを治療するための方法及び組成物
|
US20230272039A1
(en)
|
2020-07-16 |
2023-08-31 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
US20230330227A1
(en)
|
2020-08-13 |
2023-10-19 |
A2 Biotherapeutics, Inc. |
Gene fusions for control of genetically modified cells
|
US20230303665A1
(en)
|
2020-08-28 |
2023-09-28 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
IL301955A
(en)
|
2020-10-07 |
2023-06-01 |
Asklepios Biopharmaceutical Inc |
Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
EP4232566A1
(de)
|
2020-10-22 |
2023-08-30 |
Lyell Immunopharma, Inc. |
Chimäre aktivierungsrezeptoren
|
KR20230098201A
(ko)
|
2020-10-26 |
2023-07-03 |
네오이뮨텍, 인코퍼레이티드 |
줄기 세포 동원의 유도 방법
|
AU2021367952A1
(en)
|
2020-10-26 |
2023-06-08 |
Sola Biosciences Llc |
Compositions and methods for the treatment of alzheimer's disease
|
US20240101629A1
(en)
|
2020-11-02 |
2024-03-28 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
JP2023550309A
(ja)
|
2020-11-04 |
2023-12-01 |
セルジーン コーポレーション |
以前に抗がんアルキル化剤療法を受けた患者におけるcar t細胞療法
|
AU2021376396A1
(en)
|
2020-11-05 |
2023-06-08 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
CA3196677A1
(en)
|
2020-11-05 |
2022-05-12 |
Erik Hans MANTING |
Use of tumor-independent antigens in immunotherapies
|
IL302728A
(en)
|
2020-11-13 |
2023-07-01 |
Catamaran Bio Inc |
Genetically modified natural killer cells and methods of using them
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
EP4272002A1
(de)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Verwendungen von chimären antigenrezeptor(car)-t-zelltherapien in kombination mit inhibitoren von entzündungsverwandten löslichen faktoren
|
JP2023552531A
(ja)
|
2020-12-10 |
2023-12-18 |
サレプタ セラピューティクス, インコーポレイテッド |
接着細胞のための懸濁モードシードトレイン開発
|
WO2022132596A2
(en)
|
2020-12-14 |
2022-06-23 |
Biontech Us Inc. |
Tissue-specific antigens for cancer immunotherapy
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
CA3204161A1
(en)
|
2021-01-11 |
2022-07-14 |
Jagesh Vijaykumar SHAH |
Use of cd8-targeted viral vectors
|
WO2022164935A1
(en)
|
2021-01-27 |
2022-08-04 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
EP4284440A1
(de)
|
2021-01-30 |
2023-12-06 |
Universitat Autònoma De Barcelona |
Gentherapie für monogene diabetes
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
BR112023018987A2
(pt)
|
2021-03-19 |
2023-12-05 |
Glaxosmithkline Ip Dev Ltd |
Receptores de antígenos quiméricos direcionados à claudina-3 e métodos de tratamento do câncer
|
WO2022204071A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
CN117321417A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
确定治疗性细胞组合物的效力的方法
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
WO2022221462A1
(en)
|
2021-04-13 |
2022-10-20 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
|
IL307598A
(en)
|
2021-04-16 |
2023-12-01 |
Juno Therapeutics Inc |
T-cell therapy in patients who have had a previous stem cell transplant
|
AU2022270611A1
(en)
|
2021-05-03 |
2023-10-12 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature corneal endothelial cells
|
CA3217862A1
(en)
|
2021-05-05 |
2022-11-10 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|
EP4334354A1
(de)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen alk und verfahren zur verwendung davon
|
TW202309268A
(zh)
|
2021-05-07 |
2023-03-01 |
安斯泰來再生醫藥協會 |
產生成熟肝細胞的方法
|
EP4089171A1
(de)
|
2021-05-12 |
2022-11-16 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Rekombinante tert-codierende virale genome und vektoren
|
WO2022251443A1
(en)
|
2021-05-26 |
2022-12-01 |
FUJIFILM Cellular Dynamics, Inc. |
Methods to prevent rapid silencing of genes in pluripotent stem cells
|
EP4347619A2
(de)
|
2021-05-26 |
2024-04-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Von hexokinase abgeleitete peptide und deren therapeutische verwendungen
|
CN117642420A
(zh)
|
2021-05-28 |
2024-03-01 |
萨那生物科技公司 |
含有截短的狒狒内源性逆转录病毒(BaEV)包膜糖蛋白的脂质颗粒及相关方法和用途
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022256437A1
(en)
|
2021-06-02 |
2022-12-08 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022258606A1
(en)
|
2021-06-07 |
2022-12-15 |
Gadeta B.V. |
Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
KR20240021898A
(ko)
|
2021-06-14 |
2024-02-19 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
돌연변이된 아넥신 a5 폴리펩타이드 및 치료 목적을 위한 이의 용도
|
EP4355768A1
(de)
|
2021-06-14 |
2024-04-24 |
Takeda Pharmaceutical Company Limited |
Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression
|
AR126145A1
(es)
|
2021-06-15 |
2023-09-13 |
Takeda Pharmaceuticals Co |
Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes
|
EP4362957A1
(de)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Manipulierte natürliche killerzellen (nk) und zugehörige verfahren
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023285700A1
(en)
|
2021-07-16 |
2023-01-19 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Oligonucleotide for inhibiting quaking activity
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
CA3223636A1
(en)
|
2021-08-06 |
2023-02-09 |
Christopher Walton CARROLL |
Compositions and methods for selective degradation of engineered proteins
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
IL310862A
(en)
|
2021-08-16 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Antibodies against FLT3, chimeric antigen receptors, chimeric antigen receptor T cells and methods of use
|
IL311725A
(en)
|
2021-09-30 |
2024-05-01 |
Bioverativ Therapeutics Inc |
Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
WO2023077107A1
(en)
|
2021-10-29 |
2023-05-04 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023115049A1
(en)
|
2021-12-17 |
2023-06-22 |
Umoja Biopharma, Inc. |
Cytotoxic innate lymphoid cell and uses thereof
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
WO2023172694A1
(en)
|
2022-03-09 |
2023-09-14 |
Dana-Farber Cancer Institute, Inc. |
Genetically engineered b cells and methods of use thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
WO2023212683A1
(en)
|
2022-04-29 |
2023-11-02 |
Kriya Therapeutics, Inc. |
Insulin and glucokinase gene therapy compositions and its use for treating diabetes
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
US20240002800A1
(en)
|
2022-05-16 |
2024-01-04 |
Mendus B.V. |
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
WO2023225160A1
(en)
|
2022-05-18 |
2023-11-23 |
The Children's Hospital Of Philadelphia |
Compositions and methods for inducible alternative splicing regulation of gene expression
|
WO2023227594A1
(en)
|
2022-05-24 |
2023-11-30 |
Gadeta Bv |
Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
WO2023237541A1
(en)
|
2022-06-07 |
2023-12-14 |
Gadeta B.V. |
Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
WO2023240282A1
(en)
|
2022-06-10 |
2023-12-14 |
Umoja Biopharma, Inc. |
Engineered stem cells and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US20240003871A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Ipsc-derived astrocytes and methods of use thereof
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|
WO2024013401A1
(en)
|
2022-07-15 |
2024-01-18 |
Gadeta B.V. |
Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024018003A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026490A1
(en)
|
2022-07-28 |
2024-02-01 |
Sqz Biotechnologies Company |
Polynucleotides encoding linked antigens and uses thereof
|
WO2024031060A1
(en)
|
2022-08-04 |
2024-02-08 |
Elevatebio Technologies, Inc. |
Lentiviral vectors and uses thereof
|
WO2024038002A1
(en)
|
2022-08-15 |
2024-02-22 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of adverse effects related to recombinant viral vectors
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
WO2024052413A1
(en)
|
2022-09-07 |
2024-03-14 |
Universitat Autònoma De Barcelona |
Beta-hexosaminidase vectors
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024097992A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Particles displaying adhesion-molecule fusions
|
WO2024098028A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Lentiviral particles displaying fusion molecules and uses thereof
|
WO2024098038A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Polynucleotide construct and related viral vectors and methods
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
WO2024100136A1
(en)
|
2022-11-08 |
2024-05-16 |
Gadeta B.V. |
Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
|